Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Commentary

Rational use of Xpert testing in patients with presumptive TB: clinicians should be encouraged to use the test-treat threshold

Authors: Tom Decroo, Aquiles R. Henríquez-Trujillo, Anja De Weggheleire, Lutgarde Lynen

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

A recently published Ugandan study on tuberculosis (TB) diagnosis in HIV-positive patients with presumptive smear-negative TB, which showed that out of 90 patients who started TB treatment, 20% (18/90) had a positive Xpert MTB/RIF (Xpert) test, 24% (22/90) had a negative Xpert test, and 56% (50/90) were started without Xpert testing. Although Xpert testing was available, clinicians did not use it systematically. Here we aim to show more objectively the process of clinical decision-making.
First, we estimated that pre-test probability of TB, or the prevalence of TB in smear-negative HIV infected patients with signs of presumptive TB in Uganda, was 17%. Second, we argue that the treatment threshold, the probability of disease at which the utility of treating and not treating is the same, and above which treatment should be started, should be determined. In Uganda, the treatment threshold was not yet formally established. In Rwanda, the calculated treatment threshold was 12%. Hence, one could argue that the threshold was reached without even considering additional tests. Still, Xpert testing can be useful when the probability of disease is above the treatment threshold, but only when a negative Xpert result can lower the probability of disease enough to cross the treatment threshold. This occurs when the pre-test probability is lower than the test-treat threshold, the probability of disease at which the utility of testing and the utility of treating without testing is the same. We estimated that the test-treatment threshold was 28%. Finally, to show the effect of the presence or absence of arguments on the probability of TB, we use confirming and excluding power, and a log10 odds scale to combine arguments.

Conclusion

If the pre-test probability is above the test-treat threshold, empirical treatment is justified, because even a negative Xpert will not lower the post-test probability below the treatment threshold. However, Xpert testing for the diagnosis of TB should be performed in patients for whom the probability of TB was lower than the test-treat threshold. Especially in resource constrained settings clinicians should be encouraged to take clinical decisions and use scarce resources rationally.
Literature
1.
go back to reference Hermans SM, Babirye JA, Mbabazi O, Kakooza F, Colebunders R, Castelnuovo B, et al. Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort study. BMC Infect Dis. 2017;17(1):433.CrossRefPubMedPubMedCentral Hermans SM, Babirye JA, Mbabazi O, Kakooza F, Colebunders R, Castelnuovo B, et al. Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort study. BMC Infect Dis. 2017;17(1):433.CrossRefPubMedPubMedCentral
2.
go back to reference Whiting PF, Davenport C, Jameson C, Burke M, Sterne JA, Hyde C, et al. How well do health professionals interpret diagnostic information? A systematic review. BMJ Open. 2015;5(7):e008155.CrossRefPubMedPubMedCentral Whiting PF, Davenport C, Jameson C, Burke M, Sterne JA, Hyde C, et al. How well do health professionals interpret diagnostic information? A systematic review. BMJ Open. 2015;5(7):e008155.CrossRefPubMedPubMedCentral
3.
go back to reference Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;1:CD009593. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;1:CD009593.
4.
go back to reference Pauker SG, Kassirer JP. Therapeutic decision making: a cost-benefit analysis. N Engl J Med. 1975;293(5):229–34.CrossRefPubMed Pauker SG, Kassirer JP. Therapeutic decision making: a cost-benefit analysis. N Engl J Med. 1975;293(5):229–34.CrossRefPubMed
5.
go back to reference Basinga P, Moreira J, Bisoffi Z, Bisig B, Van den Ende J. Why are clinicians reluctant to treat smear-negative tuberculosis? An inquiry about treatment thresholds in Rwanda. Med Decis Mak. 2007;27(1):53–60.CrossRef Basinga P, Moreira J, Bisoffi Z, Bisig B, Van den Ende J. Why are clinicians reluctant to treat smear-negative tuberculosis? An inquiry about treatment thresholds in Rwanda. Med Decis Mak. 2007;27(1):53–60.CrossRef
7.
go back to reference Hunink MGM. Decision making in health and medicine: integrating evidence and values. 2nd ed. Cambridge: Cambridge University Press; 2014.CrossRef Hunink MGM. Decision making in health and medicine: integrating evidence and values. 2nd ed. Cambridge: Cambridge University Press; 2014.CrossRef
8.
go back to reference Boyles TH. Why do clinical trials of Xpert® MTB/RIF fail to show an effect on patient relevant outcomes? Int J Tuberc Lung Dis. 2017;21(3):249–50.CrossRefPubMed Boyles TH. Why do clinical trials of Xpert® MTB/RIF fail to show an effect on patient relevant outcomes? Int J Tuberc Lung Dis. 2017;21(3):249–50.CrossRefPubMed
9.
go back to reference Pauker SG, Kassirer JP. The threshold approach to clinical decision making. N Engl J Med. 1980;302(20):1109–17.CrossRefPubMed Pauker SG, Kassirer JP. The threshold approach to clinical decision making. N Engl J Med. 1980;302(20):1109–17.CrossRefPubMed
10.
go back to reference Van den Ende J, Moreira J, Basinga P, Bisoffi Z. The trouble with likelihood ratios. Lancet. 2005;366(9485):548.CrossRefPubMed Van den Ende J, Moreira J, Basinga P, Bisoffi Z. The trouble with likelihood ratios. Lancet. 2005;366(9485):548.CrossRefPubMed
11.
go back to reference Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet. 2005;365(9469):1500–5.CrossRefPubMed Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet. 2005;365(9469):1500–5.CrossRefPubMed
12.
go back to reference Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med. 2010;362(8):707–16.CrossRefPubMed Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med. 2010;362(8):707–16.CrossRefPubMed
13.
go back to reference Van den Ende J, Bisoffi Z, Van Puymbroek H, Van der Stuyft P, Van Gompel A, Derese A, et al. Bridging the gap between clinical practice and diagnostic clinical epidemiology: pilot experiences with a didactic model based on a logarithmic scale. J Eval Clin Pract. 2007;13(3):374–80.CrossRefPubMed Van den Ende J, Bisoffi Z, Van Puymbroek H, Van der Stuyft P, Van Gompel A, Derese A, et al. Bridging the gap between clinical practice and diagnostic clinical epidemiology: pilot experiences with a didactic model based on a logarithmic scale. J Eval Clin Pract. 2007;13(3):374–80.CrossRefPubMed
Metadata
Title
Rational use of Xpert testing in patients with presumptive TB: clinicians should be encouraged to use the test-treat threshold
Authors
Tom Decroo
Aquiles R. Henríquez-Trujillo
Anja De Weggheleire
Lutgarde Lynen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2798-6

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue